MEMORY PHARMACEUTICALS REPORTS RESULTS FROM STUDY OF MEM 1003 IN ALZHEIMER'S PATIENTS
Memory Pharmaceuticals has announced preliminary results from its Phase Ib safety
and tolerability study of MEM 1003 in Alzheimer's disease patients. In the study,
MEM 1003 was safe and generally well-tolerated at the dose ranges tested. In
addition, the results demonstrated that MEM 1003 is cognitively safe in patients
with Alzheimer's disease.
The study consisted of two segments — a double-blind dose-escalation segment
and a double-blind multiple-dose treatment segment. In the first segment of
the study, MEM 1003 or placebo was administered to 49 patients two times on
one day. Patients in this segment of the study were treated at escalating doses
of MEM 1003 that reached 120 mg per dose two times per day. In the double-blind
multiple dose treatment segment, 32 patients received 120 mg of MEM 1003 or
placebo twice daily for a period of ten days.